2 biotech shares with explosive potential

Bionomics Ltd (ASX:BNO) is one of two companies looking to follow in the footsteps of biotech giant CSL Limited (ASX:CSL). Should you invest today?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When it comes to biotech shares on the Australian stock exchange there is one company that towers above them all. That is of course $48 billion-giant CSL Limited (ASX: CSL).

I believe the global specialty biotechnology company is one of highest quality companies on the market and is capable of delivering solid earnings growth for at least the next decade. For this reason I feel it would make a great long-term buy and hold investment.

I'm sure many smaller biotech companies will have aspirations to follow in the footsteps of CSL and become a giant in the industry. Whilst finding the next CSL when it is a small cap might be wishful thinking, I do believe these two biotechs have explosive growth prospects that make them worth keeping a close eye on today. Here they are:

Bionomics Ltd (ASX: BNO)

The shares of this Adelaide-based biopharmaceutical company have been on a tear in the last month, climbing a staggering 44% during that time. The reason for the strong gains can largely be attributed to the promising phase II trial results of its BNC210 drug for the treatment of anxiety. According to the release the drug suppressed activation of the amygdala and outperformed the current standard of care, Ativan.

This is a very promising development for the company, but only one of a number in its pipeline. In partnership with US$174 billion pharmaceutical giant Merck & Co, the company aims to bring new treatments to patients suffering from chronic pain and memory impairment. These include those with ADHD, Alzheimer's Disease, Parkinson's disease and Schizophrenia. Following the sharp rise in its value it might be worth waiting for a dip in its share price before making any investment.

Viralytics Ltd. (ASX: VLA)

Viralytics is a company intent on developing novel cancer treatments. On Monday the company updated the market on the use of its CAVATAK product in the treatment of both melanoma and non-muscle invasive bladder cancer. CAVATAK is a novel cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and attack cancer cells. It has been designed to enhance the body's own defences in fighting cancer.

Both trials have produced positive results and it comes as little surprise to see its share price rally by over 12% since the announcement. According to a research note out of Roth Capital, its analysts estimate that CAVATAK's use in melanoma treatment could deliver sales of US$600 million a year eventually. It is still early days and there are a number of trials and regulatory approvals needed before it hits the market, so investors may be best adding Viralytics to their watch list for the time being.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »